Oncology Today with Dr Neil Love
Oncology Today with Dr Neil Love
✓

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

· afficher les notes
00:47:06
Podcasts
RSS
Link

À PROPOS DE CET ÉPISODE

Featuring an interview with Dr L Elizabeth Budde, including the following topics:

  • Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
  • Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
  • Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
  • Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
  • Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
  • Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)

CME information and select publications

Médecine
Éducation
Forme et santé
Médecine
Sciences
Anglais
États-Unis
UtilisezAPIpour récupérer cet épisode dansJSON

DANS CET ÉPISODE

Modifier ces tags

MONTRER LES NOTES 🔗

00:00:00Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy
00:07:35Management of BsAb-induced cytokine release syndrome and other toxicities
00:17:30Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study
00:23:18Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting
00:32:52Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting
00:37:35Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin

TRANSCRIPTION 🔗

Are you the producer of this podcast? Add a podcast transcript
Need Audio-to-Text? Transcribe with Listen411 in Just 60 Seconds

RECHERCHER LES ÉPISODES PASSÉS

Rechercher les épisodes précédents de Oncology Today with Dr Neil Love.
Intégrez cette barre de recherche à votre site Web

AUTRES ÉPISODES DANS CE PODCAST

Ovarian Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Ovarian Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula Ma…
00:12:17
PARTAGER
ENREGISTRER
Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Featuring a slide presentation from Dr Julia Rotow, including the following topics: Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00) Key findings from the Phase III HA…
00:24:03
PARTAGER
ENREGISTRER
Chronic Lymphocytic Leukemia — Microlearning Activity 2

Chronic Lymphocytic Leukemia — Microlearning Activity 2

Featuring perspectives from Dr Catherine C Coombs, including the following topics: Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00) Role of…
00:27:51
PARTAGER
ENREGISTRER
Chronic Lymphocytic Leukemia — Microlearning Activity 1

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Featuring perspectives from Dr Catherine C Coombs, including the following topics: Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00) Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor the…
00:24:32
PARTAGER
ENREGISTRER
Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics: Introduction and Overview of Bispecific Antibodies in the Clinic (0:00) Current and …
01:58:22
PARTAGER
ENREGISTRER
Avertissement: Le podcast et les illustrations intégrés sur cette page proviennent de Dr. Neil Love, qui est la propriété de son propriétaire et n'est ni affilié ni approuvé par Listen Notes, Inc.
PROMOTED
We’re selling some of our podcast-related domain names, including breaker.fm, Podcast.mov, and Listen.Host. Place your bid on eBay.
We’re selling some of our podcast-related domain names, including breaker.fm, Podcast.mov, and Listen.Host. Place your bid on eBay.
Bid on eBay

RECOMMANDATIONS
Utiliser l'API pour extraire cet épisode